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Summary: Knowledge of gene analysis methods and concepts will be important to the clinical chemist in the
near future. Currently most gene analyses must be performed by indirect techniques, using polymicleotide
probes hybridizing close to or on the disease gene but not on the position of the mostly unknown gene
mutation (restriction fragment length polymorphism analysis). The sensitivity and specificity of such assays
are affected by biological and methodologic factors, and are being continually improved. Preventive medicine
is a promising area for gene analysis which will possibly fit well into the domain of clinical chemistry. The
application of nucleotide hybridization analysis in tissue matching for organ transplantation, and in the
detection and differential diagnosis of malignancies is in its early stages. A very promising, and rapidly
emerging, technology is the direct detection and differentiation by gene probing of bacteria and viruses in
medical microbiology. Guidelines for the ethical problems of gene analysis already exist within the field of
medical ethics.
Introduction
Modern methods of gene analysis can be applied to
many fields of medicine. This presentation attempts
to assess the impact of gene analysis on clinical che-
mistry, äs seen by a clinical chemist. The discussion
focuses on three topics:
(1) methodologieal characteristics,
(2) some of the applications of gene analysis, and
(3) the public debate äbout the impact of gene analy-
sis on the individual and society.
Methodology
Several aspects of polynucleotide hybridization tech-
nology need to be fürther developed' for routine use
in clinical chemistry. The mäin goäls for tihis develop-
ment are to increase the specificity, sensitivity, and
speed of analysis, to make the use of radioactive
labelling unnecessary, to automate analysis, and to
increase the cost/benefit ratio.
!) Revised manuscript of a lecture presented in the Workshop
on "Analysis of Genetic Defects by Molecular Biology
Methods" at the Congress "Biochemical Analysis 86", Mu-
nich, June 2, 1986.
Table l reviews the different procedures of hybridiz-
ation technology. Some subheadings have been added
under the "Southern blot" technique to demonstrate
the improvements in cleavage and Separation of
PNA/RNA. The* Southern blot technique is ad-
dressed in figure l, which depicts in a very simplified
way the two basic forms of application:
direct analysis, with probes hybridizing directly on,
the position of a gene defect, and
indirect analysis, with probes hybridizing in a position
close to, but not directly on, the gene defect itself.
The latter is called restriction fragment length poly-
morphism (RFLP) analysis, because the length of
the DNA fragment visualized with the probe differs
depending on the presence or absence of a gene
mutation.
Today only a few gene defects can be analyzed with
direct probes; indirect restriction fragment length
polymorphism methodology has to be used for the
majority of tests (8). This technique, however, only
provides statistical evidence: a positive or negative
test result is based on the establishment by analytical
and biostatistical methods of a reliable correlation
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Tab. t. Gene analysis: Procedures (1-4).
Procedure Example
In situ hybridization
Dot blot technique
Colony hybridization
Plaque hybridization
Sourthern blot
Conventional restriction enzymes
"Universal" restriction enzymes (5)
"Oligomer restriction" (6)
Pulsed field electrophoresis (7)
Northern blot
Chromosomal localization
Semiquantitative detection of extracted DNA
Dot blot for bacterial cultures
Dot blot for viral cultures ·'f
RFLP, point mutations, deletipns, etc.
(Homogeneous technique)
(Separation of high moleeular weight DNA)
Gene detection with m-RNA
Oirect Analysis
N H A
Indired Analysis: Restriction Fragment Length Polyjnorphisms
N H A
Fig. 1. Gene analysis: "Southern blot" technique. Schematic
representation of a gene section with cleavage sites for
restriction enzymes. Direct analysis: A probe is available
binding on the gene mutation. After cleavage, on the
Separation gel a band will be detected in the samples
from homozygous and heterozygous persons. Indirect
analysis: A probe is available binding in some distance
from the gene mutation. When the mutation eliminates
the restriction cleavage site, the probe will mark a band
of higher molecular weight in the Separation gel. Nor-
mals show a band of lower molecular weight, homo-
zygous patients show a band of higher molecular
weight, heterozygous carriers show both bands.
N = normal person, H = heterozygous carrier, A =
affected homozygous patient, = gene mutation
("linkage") between appearance of a defmed restric-
tion fragment and a gene defect (l, 9). This is usually
achieved by moving the probes stepwise closer to the
gene defect ("gene walking, gene jumping") until a
"direct" probe has been found (10).
The clinical chemist is basically interested iri judging
the validity of diagnostic Information obtained with
gene analysis methods. Both biological and methodo-
logical factors influence the sensitivity and specificity
of the results. Some examples of biological factors
affecting the validity of test results are described
below.
— Association of disease with the marker gene chosen:
This affects the risk prediction for diseäses. If
HLA gene polymorphisms are üsed to predict the
risk for typel diabetes, the sensitivity is only
about 30%, because the disease and the marker
gene are only loosely associated (11).
— Penetrance of gene defects: This affects the risk
prediction for disease Manifestation. Penetrance
is the percentage of gene-defect carriers with
manifest disease. The sensitivity of predicting can-
cer risk for specific organs by testing for (acti-
vated) oncogenes is about 50% because most of
the tissue located oncogenes have a penetrance of
this order of magnitude (13).. The sensitivity of
predicting the risk for Hunfington's disease by
testing for a direct Huntington marker would be
nearly 100%, because this disease has an almost
absolute penetrance (14).
*- Genetic constellation ofthefamily: The linkage of
diseäses with genetic markers depends upon the
genetic constellation of a family; it is "family
specific". Assessment of the risk for genetic dis-
eäses with restriction fragment length polyinorph-
ism markers is only possible after the linkage has
been estäblished by testing äs many members of
the patients family äs possible (15).
— Linkage of marker genes with gene defects: This
affects the error probability öf gene analysis. The
Problem has already been addressed with regard
to restriction fragment length polymorphism
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methodology. The linkage depends upon the dis-
tance between the gene defect and the marker
Position. The greater the distance, the greater the
probability of a crossing over during the meiotic
phase of cell division, resulting in uncoupling of
the marker from the defect position. The unit of
measure for this distance is the Morgan: one centi-
Morgan is equivalent to about one million base
pairs, and this distance is — with notable excep-
tions — equivalent to a crossing over probability
of 1%, which means an error probability of 1%
(16). For instance, the Huntington marker of Gu-
sella (1983) binds at a distance of 5c-Morgan
from the gene defect. Therefore the sensitivity of
a positive test with this marker is 95% (14). A
good marker should be positioned at a distance
of less than 0.2 c-Morgan from the gene defect,
which translates to a sensitivity of 99.8% (9). The
sensitivity can be improved considerably by using
two probes binding on both sides of a gene defect.
Some methodologcical factors that have significant
effects on the sensitivity and specificity of hybrid-
ization assays are the choices of technique and labell-
ing system, degree of Separation attained, length of
the DNA used äs a probe, and the nucleic acid
selected for hybridization. Most of these problems
are self-evident to the clinical chemist, so only two
of them will be addressed further.
— The signal-generating label system used is directly
responsible for the assay sensitivity. Table 2 shows
a few examples of the large variety of labels pub-
lished. The Standard label is 32P, resulting in an
absolute sensitivity of 0.5 pg DNA. In recent
years, great effprts have been made to develop
non-radioactive detection Systems. With the most
elaborate enzyme-labelled biotin-avidin Systems,
a sensitivity of l pg DNA is routinely obtained.
It is only a matter of time until non-radioactive
labels will be aVailable that give equal or better
sensitivity than the 3*P label.
Tab. 2. Gene analysis: Labeling of probes (3, 17, 18).
Radioactive labels
DNA - 32P
DNA - 3H/35S (In situ hybridization)
Absolute sensitivity
' 0,5 pg
Non-radioactive labels
DNA — Fluorochrome 100 pg
DNA — Enzyme
DNA — Antibody — Enzyme
DNA — Hapten — Antibody — Enzyme
DNA — Biotin — Avidin — Enzyme l pg
DNA - Lummol - Activator — DNA ?
DNA - Biotin - Antibody - Gold (In situ
hybridization)
— Assay sensitivity and specificity can be greatly
enhanced by hybridization with nucleic acid spe-
cies other than chromosomal DNA. Table 3 sum-
marizes the variants used in gene analysis. In
clinical microbiology, for instance, the use of pro-
bes for RNA in bacterial ribosomes makes it
possible to detect bacteria with greater sensitivity.
r-RNA is present in higher concentration than
chromosomal DNA: up to 5000 copies per cell.
Tab. 3. Gene analysis: Optimization of hybridization.
Goal: Increasing sensitivity
Probe Analyte Example
DNA DNA Kinetics of association: precipi-
tants
n(DNA) DNA Several probes
DNA m-RNA Increased stability of binding
DNA r- RNA Higher copy number (19)
Goal: Increasing specificity
Probe Analyte Example
DNA m-RJMA '"%. In situ: gene activation (20)
DNA p-DNA Antibiotics resistance (21)
Enterotoxin genes (22)
Table 4 surveys the variety of sample materials that
can be used for hybridization assays. It is interesting
that modern cell sorting equipment has made it pos-
sible to isolate fetal cells from the mother's blood
eells (l fetal cell in 2.5 million blood cells). This
technique will possibly facilitate prenatal screening
procedures.
Tab. 4. Gene analysis: Sample materials.
Sample materials
Blood
Blood cells (nucleated cells)
Tissue cells
Tissues
Fibröblast cultures
Spenn cells
Hair roots
Feces
Fetal cells
from amniotic fluid
from chorionic villi
from maternal blood
Chromosomes
Application (examples)
Infection: bacteria, viruses
Genetic diseases
Malignant diseases
Identity
Exposure
Genetic diseases
Tissue typing (transplantation)
Disease predisposition
Oncogenes
In situ hybridization:
Papilloma virus infection
Genetic disease carriers
Identity
Identity
Infection: viruses
Genetic diseases
Genetic research: gene mapping
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Application of Gene Analysis
Application of the hybridization technique should be
restricted to areas in which it has defmite advantages
over classical techniques such äs analysis of gene
products by enzymatic or immunological assays.
Some instances in which hybridization assays should
be applied are:
(1) if therapy depends upon test result,
(2) if test accelerates diagnosis,
(3) if no gene product is known
(4) if there is no concordance between DNA and
gene product,
(5) if differential diagnosis via the gene product is
too complicated or inadequate, and
(6) if the test result is more accurate than with other
techniques.
This list will certainly be extended in the future.
The applications for DNA/RNA probe techniques
are expanding\rapidly. Table 5 gives a — necessarily
incomplete — list of such applications. A few of
these applications which are of special interest for the
clinical chemist will be discussed in some detail.
Prenatal and carrier diagnosis of genetic diseases is
no topic of this review. It in principle is connected
with genetic counseling and therefore is a domain of
the human geneticist.
Tab. 5. Gene analysis: Areas of application.
Area
Human genetics
Genetic diseases
Preventive medicine
Occupational medicine
Pharmacogenetics
Malignant diseases
Transplantation
Forensic medicine
Heterologous insemination
Genetic research
Detection of pathogens
Infectious diseases
Parasitic diseases
Application
Prenatal and carrier diagnosis (15,
25, 27)
Environmental diseases (14, 28)
Preventive toxicology (14, 25)
Chemotherapy (61)
Diagnosis, differentiation (29)
Organ matching (26)
Human linkage (23, 24)
Donor testing (25)
Cytogenetics (30, 31)
Bacteria, viruses (32, 33, 34)
Diagnosis, therapy monitoring
(35)
Preventive medicine is an interesting application for
which clinical chemists should investigate gene analy-
sis. The goal of this investigation is to detect persons
at risk for certain diseases by pinpointing gene de-
fects. Some of the diseases for which DNA probes
are available are e.g. atherosclerosis (36), alcohol
intolerance (37, 37a), and emphysema (38). Gene
analysis would be particularly useful for identifying
individuals at risk for the environmental diseases of
developed countries and for diseases for which no
adequate biochemical markers are available. In this
connection, an intensive search for the location of
genetic defects for diseases äs multiple sclerosis, Alz-
heimer's disease, manic depressionj rand diabetes is in
progress.
It should be realized that environmental diseases have
a multifactorial etiology. In addition to genetic pre-
disposition, factors such äs the lifestyle öf the indivi-
dual have a significant influence on the development
of these diseases. The problems of screening pro-
grams, which are well known to the clinical chemist,
also apply to preventive genetic analysis. The task is
not only to identify the carrier of a genetic defect,
but to identify carriers of the defect who are prpne
to develop disease. The measure for this probability
is the "relative risk". It equals the percentage of
defect carriers with disease manifestations, divided
by the percentage of defect carriers without disease
manifestations. Thus, a predictive valüe of a positive
test in excess of 0.9 can only be obtained in patient
samples in which the prevalence of defect carriers is
greater than 10% and with markers indicating a
relative risk of more than 100 (39). In addition* in-
creasing knowledge about the heterogeneity of ge^
netic defects (see e.g. I.e. (12)) leads to a further
complication in defining individual "genetic predis-
position". Therefore. the value of preventive genetic
health screenirig will be restricted to carefülly selected
risk groups.
A widely discussed example is Occupational screening'.
the attempt to assess the risk for employees ("hyper-
susceptibility") by detecting genetic predispositions
for Occupational hazards, e. g., exposure to chemicals,
air pollution, or extreme stress situations. Some
chemical companies, äs well äs some government
agencies in the U. S., have been utilizing such tests.
However, äs has been pointed out with regard to
preventive health testing, the problems of multifacto-
rial etiology and statistical significance apply to oecü-
pational testing. In addition, the genetic markers
tested are not necessarily associated with susceptibil-
ity, and no cost/benefit analyses have been per-
formed. Accordingly, the responsible authorities have
stopped performing these tests in most cases. Intensi-
fied ecogenetic research is necessary to provide a firm
basis for such activities (14, 25, 40).
A field of great promise is pharmacogenetics. The
possibility to determine the "genetic phenotype" of
patients regarding their response to drugs certainly
will be an important step in optimizing chempther-
apy.
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It is of considerable interest to the work of the clinical
chemist to note how laboratory testing in the field of
malignant diseases will be influenced by the hybrid-
ization technique. It is difficult to predict the extent
to which gene analysis will advance the use of bio-
chemical techniques in cancer management. However,
in some cases the use of DNA probes has already
been proven to have a definite advantage in the
detection or differential diagnosis of cancer, äs shown
in table 6.
Tab. 6. Gene analysis: Diagnosis of malignant diseases.
Immunoglobulin synthesis (29, 41)
Southern blot analysis with probe against chromosomal immu-
noglobulin genes
Detection of malignant B-cell clones
Diagnosis of lymphomas
Receptors (29)
Southern biot analysis with probe against T-cell receptor gene
Diagnosis of acute lymphoblastic ieukaemias
Oncogenes (l, 41-43)
1. Chromosomal translocations
Detection in situ, restriction fragment length polymorphism
in development
2. Gene amplification
Southern blot analysis with probe against chromosome 13
Fragments
Diagnosis of retinoblastomas
The detection of malignant B-cell clones is impor-
tant in the differential diagnosis of non-Hodgkin
lymphomas. Today, DNA probes are available
for particular regions of chromosomal immuno-
globulin genes. New restriction patterns are con-
stantly being generated äs a consequence of intra-
chromosomal gene rearrangement; the cell-spe-
cific IgO molecüle is a different one in each new B-
cell clone. Normally, these clonal immunoglobulin
species cannöt be deteeted by restriction analysis,
because the fractipn of each new B-cell clone is
too small to be deteeted. However, if a malignant
clone increases to constitute more than l % of the
total clone populatioru its band in the hybrid-
ization assay becomes prominent.
Detection of chromosome translocations is of
definite value in the differential diagnosis of leu-
kaemia induced by activated oncogenes. For ex-
ample, proof of the translocation of sis and abl
oncogenes between chromosornes 9 and 22 is a
definitive marker in the diagnosis of chronic
myelocytie leukaemia. Today testing is done by
cytogenetic techniques (including DNA probes),
but probes for use in the restriction fragment
length polymorphism technique are being devel-
oped. The problem is that in the process of trans-
location the points at which chromosornes break
vary over a distance of about 25 kilobases; this
leads to some ambiguity in the evaluation of re-
striction fragment length polymorphism patterns.
A straightforward application of hybridization assays
is the detection of foreign RNA and DNA to dia-
gnose bacterial and viral infections in humans. Ac-
cordingly, much effort is being spent to develop
routine techniques for use in medical microbiology.
Table 7 summarizes the infectious diseases for which
probes or test kits are available. The analytical prob-
lems of this methodology are threefold:
— Low sensitivity of assays (the detection limit for
bacteria today is about l O3 cells; for viruses it is
l O4-l O5 genome copies) (29, 34);
— Radioactive labelling must still be used; and
— Preconcentration, e. g. culturing, of samples is
necessary.
Tab. 7. Gene analysis: Infectious diseases (l, 3, 17, 33, 34, 44).
Disease/Organism Probes Test
kits
1. Bacterial Diseases
1.1 Enterobacteria:
E. coli, Salmonella + +
Yersinia +
1.2 Non-Enterobacteria:
Campylobacter + -f
Legionella, Bordetella, Vibrio +
Streptococci, Staphylococci (4-)
2. Sexually transmitted diseases
Herpes simplex virus, types I and II -f -l·
Neisseria gonorrhoeae -l· (+)
Chlamydia 4- 4-
AIDS
3. Viruses
3.1 Viruses in blood
Hepatitis Virus A + (+)
Hepatitis virus B 4- -h
Hepatitis virus non-A/non-B + (+)
Cytomegalovirus, adenovirus, rubellavirus, + +
Epstein-Barr virus
3.2 Viruses in stool
Rota virus +
3.3 Viruses in tissues
Papillomavirus H- (H-)
4. Parasites
Malaria H-
It can be anticipated that these methodological short-
comings will be resolved within a short time.
An example of the use of DNA probes in medical
microbiology is their application in the diagnosis
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of bacterial infections, In addition to increasing the
sensitivity and speed of analysis, emphasis has been
placed on developing more specific assays. For in-
stance, by using probes for plasmid DNA, evidence
can be obtained about the antibiotic resistance pat-
terns (21), or about specific auxotypes (32). In addi-
tion, by using probes specific for toxin genes, evidence
can be generated about the ability of E. coli to pro-
duce endo- and exotoxins.
Implications for the Clinical Chemist
Because of the many areas to which hybridization
assays can be applied, the clinical chemist is interested
in learning what impact these new techniques might
have on his laboratory, and when.
Table 8 summarizes the predictions of several profes-
sional market analysts. It shows that the hybridiz-
ation technique will have a strong impact on medical
microbiology within the next few years and will com-
plete or replace some of the classical bacteriological
and viral culture techniques and some of the immuno-
logical methods that have just appeared on the mar-
ket (45). Within 5 years laboratories are foreseen to
routinely use hybridization assays rather than immu-
nological methods for tissue typing and äs a replace-
ment for the analysis of gene products in screening
for genetic disease. By the late 1990's hybridization
assays hopefully can be routinely used to diagnose
cancer.
Table 8. Gene analysis: Market trends.
Estimates for worldwide market (Millions US $)
Year 1985 1986 1988 1990 2000
Total
Infectious diseases
Transplantation
Genetic diseases
Cancer
2
2
—
—
—
15
25
—
—
—
50
45
5
1
-
250
100
20
25
1
650
400
50
100
100
Sources: Frost & Sullivan
Robert S. First
Drexel Burnham Lambert
Clinica
Public Debate
In the course of the controversy about the merits and
risks of modern biology, the public has been made
aware that gene analysis is a technique which could
be used to infringe upon the basic rights of the
individual. In many ways this debate has become
irrational and emotional (14, 28, 46, 47). For exam-
ple, the use of gene analysis in occupational screening
could be considered preventive medicine, but it could
also be used for genetic exploration of employees or
to bar certain classes of employees froin holding
certain positions.
To identify aspects of the controyersy on which the
clinical chemist iriust take a position, it is necessäry
to look at the arguments rationally. Table 9 shows
some points that must be considered in evaluating
the impact of gene analysis on the individual and ön
society. As can be seen, arguments have been pre-
sented for and against these points.
Tab. 9. Gene analysis: Areas of cöntradictory opinion (14, 25,
28, 46, 48, 49, 50, 51).
Individual rights
Labour
Society
Minority groups
Data protection
1. Preventive medical examinations do
not violate human dignity
2. Knowledge of predisposition before
manifestation of disease may violate
the individual's rights
1. Responsibility of employers for welfare
of employees
2. Restriction of individual rights of em-
ployees
1. Bürden for support of "protected
handicaps"
2. Duty to care for diseased and disabled
1. Protection of the individual
2. Protection of the group (equality right)
1. Duty to protect citizens
2. Confidentiality
3. Right to informational self-determina-
tion
One example is the area of "social aspects." It is valid
to ask about the extent to which society should carry
the bürden for groups with "protected handicaps."
An ärgument could be made in fävor of large scale
prenatal and preventive screening; an eqüally valid
counter-argument is the duty of society to care for
its disabled and diseased, which is even included in
the German constitution (52). Another exainple is
the area of "data protection." The duty of the author-
ities to protect citizens from härm would lead to a
System of disease prevention coupled with some
degree of social pressure and handling of personal
data. This is counterbalanced by the right to self-
determinätion, an ärgument based on the rights of
Personality that denies to authorities any right to
acquire or utilize personal data. At present there is
no consensus on the arguments about gene analysis.
As a result, various groups have formulated pölicies
about how gene analysis should be handled (53, 54).
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The clinical chemist searching for guidelines for bis
involvement in gene analysis should particularly con-
sider ethical questions concerning the analysis and
Interpretation of the human genome (46, 49, 50, 51,
55, 56). These questions include the rights of indivi-
duals äs opposed to the rights of society, and protec-
tion of the ill and disabled. Arguments concerning
"genetic health" are irrelevant because the effects of
genetic counseling, äs the experts agree, will not
change to a significant degree the gene pool of our
population. According to Professional authorities in
the field of ethics, it will not be necessary to formulate
special "gene ethics," because all problems can be
solved by means of existing medical ethics (56). Rules
that the clinical chemist can follow in his work include
adherence to the responsibility principle of ethics.
This means that he has to consider and to take the
responsibility for the possible consequences of his
work (50, 51, 57). It is considered necessary to attain
i consensus of the scientists engaged in gene analysis
j by involving the medical ethics commissions (48, 52).i
An objective and detailed consideration of ethical
problems in gene analysis was provided by the 1983
report of the President's Commission for the Study
of Ethical Problems in Medicine and Biomedical and
Behavioral Research (58). The commission advocates
that five conditions be met to ensure the use of gene
analysis to benefit the individual. These conditions
are confidentiality, autonomy (individual choice),
knowledge (instruction), well-being (usefulness via
well organized programs), and equity (equal access
of all groups). However, the Commission also believes
that overemphasis on individual rights may cause
härm to other persons, e. g., children or the disabled.
In such cases, it may be necessary to perform low-
risk procedures.
Another set of recommendations, also covering the
implications of gene analysis, was developed in 1985
by the International Conference on Bioethics in
France (59). Meanwhile, the report of the Enquete-
Kommission "Chancen und Risiken der Gentechno-
logie" (61) has been published, which contains a
detailed analysis of the Situation in Germany. Special
reference to the Situation of the clinical chemist will
be given in the document "The Role and Responsibil-
ities of the Clinical Chemist" which is being prepared
by IFCC (60).
In spite of all questions and problems connected with
the application of gene analysis to human beings, in
an educated society it could lead to an improved
quality of life, äs the President's Commission foresees
(58):
"In sum, the fundamental value of genetic screening
and counselling is their ability to enhance the oppor-
tunities for individuals to obtain Information about
their personal health and childbearing risks and to
make autonomous and noncoerced choices based on
that Information."
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